Shing-Chiu Wong, M.D.

Interventional Cardiology
Shing-Chiu Wong

Dr. S. Chiu Wong is a Professor of Medicine of the Greenberg Division of Cardiology in the Department of Medicine of the Weill Medical Colllege of Cornell University. He is the Director of Cardiac Catheterization laboratories at the New York Presbyterian- Weill Cornell Medical Center.

 Dr. Wong graduated Summa Cum Laude from Columbia College in May 1980 and received his Doctor of Medicine degree from Columbia University, College of Physicians and Surgeons in May 1984 . Following his medical internship, residency, and clinical cardiology training at St. Luke's/Roosevelt Medical Center in New York City, he spent one additional stent fellowship year in 1991 under the tutorage of Dr. Richard Schatz at Scripps's Clinic and Research Foundation in La Jolla, California. He is board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology.

After his medical training, Dr. Wong joined the Cardiology Research Foundation at the Washington Hospital in 1992 and was appointed as Director of Coronary Stent Program in 1993. In 1995, Dr. Wong spearheaded a new cardiac catheterization program at the New York Hospital Medical Center of Queens where he assumed the directorship of coronary interventions. In October 1999, Dr. Wong was recruited to the New York Presbyterian Hospital - Cornell Campus as Director of Cardiac Catheterization Laboratories.

Dr. Wong has published extensively in the field of interventional cardiology with special focus on new device angioplasty, saphenous vein graft intervention, cardiogenic shock, and drug eluting stent. His current clinical research interests include novel drug eluting stent designs, access site and PFO closure devices, percutaneous valve repair, and application of stem cell technology in the treatment of myocardial ischemia. In the past five years, Dr. Wong and his colleagues had participated in multiple US pivotal trials that led to the FDA approval of both drug eluting stents for the treatment of symptomatic obstructive coronary artery disease. Dr. Wong has recently served as the national principal investigation in the ECLIPSE trial which evaluated the safety and efficacy of an extra-vascular bio-degradable access site closure device in patients undergoing coronary or peripheral diagnostic/interventional procedures compare to the standard treatment of manual compression.

Other exciting areas of ongoing research include percutaneous treatment valvular disease states including mitral regurgitation and aortic stenosis, assessment of novel pharmacologic agents to enhance safety of angioplasty procedures.

His clinical research activities have been published in Journal of American College of Cardiology, American Journal of Cardiology, American heart Journal and he has presented his findings at numerous national and international meetings including American Heart Association, American College of Cardiology, Transcatheter Therapeutics, Summer in Seattle, Taiwan Society of Cardiology and Asia Pacific Cardiology Congress. He is recruited to serve as member of the Scientific Advisory Board of multiple major US medical device companies.


Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Oscar
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]


Selected Publications in 2007-2008:


Feldman DN, Minutello RM, Gade CL, Wong SC

Outcomes Following Immediate (Ad Hoc) Versus Staged Percutaneous Coronary Interventions (Report from the 2000 to 2001 New York State Angioplasty Registry). Am J Cardiol 2007; 99: 446-9.


Feldman DN, Gidseg DS, Gade CL, Slotwiner AJ, Juliano N, Cuomo LJ, Parikh M, Naidu S, Bergman G, Wong SC, Minutello RM. Impact of bivalirudin on long-term outcomes following PCI with drug-eluting stent s in real world clinical practice. Am Heart J. 2007; 154:695-701.


Moses JW, Weisz G, Mishkel G, Caputo R, O’Shaughnessey C, Wong SC, Fischell TA, Mooney M, Williams DO, Popma JJ, Fitzgerald P, Smith S, Kuntz RE, Collins M, Cohen SA, Leon MB.

The SIRIUS-DIRECT Trial: A Multi-Center Study of Direct Stenting Using the Sirolimus-Eluting Stent in Patients With De Novo Native Coronary Artery Lesions. Cath Cardiovas Interv 70:505–512 (2007)


Naidu SS, Wong SC, Steingart RM. Interventional therapies for heart failure in the elderly. Heart Fail Clin. 2007; (4): 485-500


Minutello RM, Gade CL, Feldman DN, Wong SC.

Long-Term Clinical Benefit of Sirolimus-Eluting Stents Compared to Bare Metal Stents in the Treatment of Saphenous Vein Graft Disease. J Interv Cardiol 2007;20:458-465.


Ho HH, Minutello R, Juliano N, Wong SC. A rare cause of acute myocardial infarction: Thrombotic thrombocytopenic purpura. Int J Cardiol 2007 Dec 6. doi:10.1016/j.ijcard.2007.08.063


Ho HH, Min JK, Minutello R, Lin F, Wong SC Bergman G.

Images in cardiovascular medicine. Calcified amorphous tumor of the heart. Circulation. 2008;117(9):e171-2.


Stone GW., Witzenbichler B , Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R, for the HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358 :2218-30.